iPS Cells & Regenerative Medicine– category –
-
Emmecell’s Magnetic Human Corneal Endothelial Cell Therapy EO2002 Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
Business Wire USA Overview Emmecell announced that its magnetic human corneal endothelial cell therapy, EO2002, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA. EO2002 is an innovative regenerat... -
Fate Therapeutics Receives FDA IND Approval for CAR-T Therapy FT839 for Autoimmune Diseases, Advancing to Phase 1/2 Clinical Trial
GlobeNewswire USA Overview Fate Therapeutics has received U.S. FDA Investigational New Drug (IND) approval for its CAR-T cell therapy candidate, FT839, targeting autoimmune diseases. The company plans to initiate a Phase 1/2 basket clini... -
RoosterBio and Applied StemCell Announce Strategic Partnership for iPSC-Based Bioprocess Solutions
BioSpace USA Overview RoosterBio and Applied StemCell have announced a strategic partnership aimed at developing and commercializing iPSC-based bioprocess solutions. This collaboration combines Applied StemCell's GMP-compatible iPSC tech... -
VCU-Led Team Develops Novel Cancer Drug Discovery Platform Leveraging 3D Bioprinting and AI for Rapid Therapy Identification
VCU Massey Comprehensive Cancer Center USA Overview A scientific team from VCU Massey Comprehensive Cancer Center, UCLA Health Jonsson Comprehensive Cancer Center, and the University of Colorado School of Medicine has developed a new pla... -
RoslinCT and BlueRock Therapeutics Partner to Expand Supply of Clinical-Grade iPSC Lines, Supporting Cell Therapy Development
PharmaSource UK Overview RoslinCT has announced a strategic partnership with BlueRock Therapeutics to expand access to clinical-grade iPSC lines for cell therapy developers. This collaboration integrates BlueRock's high-quality clinical-... -
Siren Biotechnology Secures $8 Million Non-Dilutive Funding from CIRM to Advance Brain Tumor Gene Therapy SRN-101
Phacilitate USA Overview Siren Biotechnology has been awarded $8 million in non-dilutive funding from the California Institute for Regenerative Medicine (CIRM). This significant capital injection will be used to support the clinical deve... -
FDA Approves Casgevy for Expanded Use in Pediatric Patients Aged 2 and Older with Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia
Seeking Alpha USA Overview Crispr Therapeutics and Vertex Pharmaceuticals announced that the U.S. FDA has approved an expanded indication for Casgevy (exagamglogene autotemcel) to include pediatric patients aged 2 and older with sickle c... -
FDA Approves Orca Bio’s Tregzi to Reduce GvHD Incidence and Improve Outcomes in Blood Cancer Patients Undergoing Allogeneic HSCT
Precision Oncology News USA Overview The U.S. FDA has approved Orca Bio's precision-engineered donor-derived cell therapy, Tregzi. Tregzi aims to significantly reduce the incidence of graft-versus-host disease (GvHD) while maintaining th... -
Catalent and Nanoscope Expand Supply Partnership for Commercialization of Optogenetic Gene Therapy MCO-010 for Retinal Degenerative Diseases
LucidQuest Ventures USA Overview Catalent and Nanoscope Therapeutics have expanded their partnership to support the late-stage development and commercial supply of MCO-010, an optogenetic gene therapy candidate for retinal degenerative d... -
STEMCELL Technologies and CCRM Partner to Accelerate Cell Therapy Development by Expanding Access to Matched GMP/RUO iPSC Lines
Business Wire USA Overview STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) have announced a strategic partnership to expand access to high-quality human iPSC starting materials. This collaborati...
